Clinical bottom line
Artificial intelligence (AI)-enhanced imaging shows promise as a tool for early detection and rupture risk stratification of intracranial aneurysms (IAs). Emerging evidence suggests that AI algorithms integrating morphological, hemodynamic, and vessel wall imaging features may improve prediction accuracy beyond traditional clinical and radiological risk factors. However, current data remain preliminary and largely retrospective, with variability in study populations and imaging protocols. AI-assisted rupture risk assessment could potentially guide personalized surveillance and intervention strategies but requires further prospective validation before routine clinical adoption.
What the evidence shows
Intracranial aneurysm rupture risk assessment is critical for clinical decision-making but remains challenging due to complex pathophysiology and heterogeneous aneurysm characteristics. Traditional risk factors include aneurysm size, location, patient smoking status, and morphological features, yet these alone insufficiently predict rupture (Zeng et al., 2023; Blogging Stroke, 2016).
Recent studies have leveraged AI to analyze high-dimensional imaging data for improved rupture risk prediction. Muhammad et al. (2023) developed StrokeNet, an automated deep learning pipeline for aneurysm segmentation and rupture risk prediction on computed tomography angiography (CTA). Their model demonstrated promising accuracy in distinguishing ruptured from unruptured aneurysms by extracting subtle shape and texture features not readily apparent to human readers.
Advanced imaging biomarkers such as wall shear stress (WSS) and vessel wall enhancement (VWE) on MRI have been correlated with aneurysm instability. Pan et al. (2020) reported that combining quantitative WSS measurements with VWE patterns improved risk stratification, suggesting that AI algorithms incorporating these parameters could enhance predictive performance.
Smoking remains a major modifiable risk factor for rupture, and its integration into AI models may refine risk estimates (Blogging Stroke, 2025). Additionally, thermodynamic and structural tissue stability analyses have been proposed to complement imaging features for rupture risk assessment (Pearson et al., 2018).
More recently, nomograms combining clinical, imaging, and procedural variables have been developed to predict early rupture and rebleeding risk post-embolization, highlighting the potential for AI-driven personalized risk models in both pre- and post-treatment settings (Du et al., 2026).
A comprehensive review by JMA Journal (2026) underscores the growing role of AI in cerebrovascular imaging, emphasizing the need for standardized datasets and prospective validation to translate these tools into clinical practice.
Caveats and uncertainty
Despite encouraging results, several limitations temper enthusiasm for immediate clinical implementation. Most AI studies to date are retrospective, single-center, or involve relatively small cohorts, raising concerns about generalizability and overfitting. Variability in imaging modalities, acquisition protocols, and annotation standards complicates model training and external validation.
The biological mechanisms linking imaging biomarkers like WSS and VWE to rupture risk remain incompletely understood, and their interpretation may be confounded by technical factors. Smoking and other clinical risk factors are often underrepresented or inconsistently integrated into AI models.
Moreover, AI algorithms typically function as "black boxes," limiting interpretability and clinician trust. Regulatory approval pathways and reimbursement frameworks for AI-based rupture risk tools are still evolving.
Finally, the clinical impact of AI-enhanced rupture risk prediction on patient outcomes, including reduction in rupture incidence or optimization of treatment timing, has not yet been demonstrated in prospective trials.
How this may change practice
AI-enhanced imaging for intracranial aneurysm rupture risk stratification represents a promising adjunct to current clinical assessment. In the near term, AI tools may assist radiologists and neurovascular specialists by providing quantitative, reproducible risk metrics that complement expert interpretation.
Such tools could enable more personalized surveillance intervals, identify high-risk aneurysms warranting earlier intervention, and potentially reduce unnecessary procedures for low-risk lesions. Integration of AI outputs into multidisciplinary decision-making workflows may improve consistency and confidence in management strategies.
However, widespread adoption will require robust prospective validation, standardization of imaging and annotation protocols, and demonstration of clinical utility and cost-effectiveness. Clinicians should remain cautious and consider AI predictions as hypothesis-generating rather than definitive until further evidence accrues.